DK3106166T3 - Forbindelser til behandling af smertesyndrom og andre lidelser - Google Patents
Forbindelser til behandling af smertesyndrom og andre lidelser Download PDFInfo
- Publication number
- DK3106166T3 DK3106166T3 DK16170030.7T DK16170030T DK3106166T3 DK 3106166 T3 DK3106166 T3 DK 3106166T3 DK 16170030 T DK16170030 T DK 16170030T DK 3106166 T3 DK3106166 T3 DK 3106166T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- connections
- treatment
- pain syndrome
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3266908P | 2008-02-29 | 2008-02-29 | |
EP09715280A EP2252608A4 (en) | 2008-02-29 | 2009-02-26 | METHOD FOR TREATING PAIN SYNDROME AND OTHER SUFFERING |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3106166T3 true DK3106166T3 (da) | 2021-01-11 |
Family
ID=41016469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16170030.7T DK3106166T3 (da) | 2008-02-29 | 2009-02-26 | Forbindelser til behandling af smertesyndrom og andre lidelser |
Country Status (8)
Country | Link |
---|---|
US (4) | US8865727B2 (da) |
EP (2) | EP2252608A4 (da) |
JP (2) | JP5723600B2 (da) |
CN (1) | CN101970427A (da) |
DK (1) | DK3106166T3 (da) |
ES (1) | ES2842289T3 (da) |
HK (1) | HK1232162A1 (da) |
WO (1) | WO2009108798A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2842289T3 (es) | 2008-02-29 | 2021-07-13 | Vm Therapeutics Llc | Compuestos para tratar el síndrome del dolor y otros trastornos |
US20130123285A1 (en) * | 2010-05-14 | 2013-05-16 | University Of Rochester | Compositions and Methods for Targeting A3G:RNA Complexes |
WO2012105594A1 (ja) * | 2011-02-01 | 2012-08-09 | 協和発酵キリン株式会社 | 縮環複素環誘導体 |
US9724348B2 (en) | 2013-03-15 | 2017-08-08 | Vm Therapeutics Llc | Crystalline forms |
KR20200046525A (ko) * | 2018-10-24 | 2020-05-07 | 건국대학교 글로컬산학협력단 | 피렌페론 화합물을 유효성분으로 포함하는 취약 x 증후군 및 관련 발달 장애치료용 조성물 |
KR102374917B1 (ko) * | 2018-10-24 | 2022-03-17 | 건국대학교 글로컬산학협력단 | 피렌페론 화합물을 유효성분으로 포함하는 취약 x 증후군 및 관련 발달 장애치료용 조성물 |
WO2022260016A1 (ja) * | 2021-06-07 | 2022-12-15 | 学校法人近畿大学 | T型カルシウムチャネル阻害剤 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
EP0181793B1 (fr) * | 1984-10-16 | 1988-07-27 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique |
US6096514A (en) | 1988-04-04 | 2000-08-01 | Sibia Neurosciences, Inc. | Human calcium channel compositions and methods |
CA1341170C (en) | 1988-04-04 | 2001-01-16 | Steven B. Ellis | Calcium channel compositions and methods |
US5876958A (en) | 1988-04-04 | 1999-03-02 | Sibia Neurosciences, Inc. | Assays of cells expressing human calcium channels containing α1 β subunits |
US5386025A (en) | 1990-02-20 | 1995-01-31 | The Salk Institute Biotechnology/Industrial Associates | Calcium channel compositions and methods |
US5874236A (en) | 1988-04-04 | 1999-02-23 | Sibia Neurosciences. Inc. | DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits |
US5846757A (en) | 1988-04-04 | 1998-12-08 | Sibia Neurosciences, Inc. | Human calcium channel α1, α2, and β subunits and assays using them |
US5407820A (en) | 1988-04-04 | 1995-04-18 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Calcium channel α-2 subunit DNAs and cells expressing them |
US5851824A (en) | 1988-04-04 | 1998-12-22 | Sibia Neurosciences, Inc. | Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA |
US5629307A (en) * | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
CA2051840A1 (en) * | 1991-09-19 | 1993-03-20 | Leo A. A. Ooms | Method of treating respiratory distress |
US5670113A (en) | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
EP0739200A4 (en) * | 1993-11-23 | 1997-12-17 | Cambridge Neuroscience Inc | SUBSTITUTED GUANIDINES FOR THERAPEUTIC USE |
JPH1035483A (ja) | 1996-07-19 | 1998-02-10 | Kayaba Ind Co Ltd | 空気浮上装置 |
CA2312195A1 (en) | 1997-12-03 | 1999-06-10 | Merck & Co., Inc. | Low-voltage activated calcium channel compositions and methods |
US6537520B1 (en) * | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
WO1999059409A1 (en) | 1998-05-21 | 1999-11-25 | Matsumoto Rae R | Compounds and uses thereof |
WO2000002455A1 (en) | 1998-07-09 | 2000-01-20 | Cv Technologies Inc. | Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics |
JP2002525077A (ja) | 1998-08-26 | 2002-08-13 | サウス、アラバマ、メディカル、サイエンス、ファウンデーション | T型カルシウムチャンネル |
JP2002540204A (ja) * | 1999-03-26 | 2002-11-26 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
ATE269848T1 (de) | 1999-04-07 | 2004-07-15 | Univ Virginia | Calciumkanalblocker als antikrebsmittel |
CA2377931A1 (en) | 1999-07-02 | 2001-01-11 | Neuromed Technologies, Inc. | Novel mammalian calcium channels and related probes, cell lines and methods |
US6783933B1 (en) | 1999-09-15 | 2004-08-31 | The Johns Hopkins University School Of Medicine | CACNA1G polynucleotide, polypeptide and methods of use therefor |
GB0007842D0 (en) | 2000-03-31 | 2000-05-17 | Spruce Barbara | Sigma receptor ligands and their medical uses |
WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
WO2003007953A1 (en) * | 2001-07-18 | 2003-01-30 | Washington University | Methods and compositions for modulating t-type calcium channels |
EP1534256A4 (en) * | 2002-06-17 | 2007-06-20 | Philadelphia Health & Educatio | IMMUNOMODULATION AND ACTION ON CELLULAR PROCESSES RELATING TO SEROTONIN FAMILY RECEPTORS AND THE HEMATO-ENCEPHALIC BARRIER |
AU2003248907B2 (en) * | 2002-07-11 | 2007-04-26 | Merck & Co., Inc. | Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds |
EP1565453A4 (en) * | 2002-11-22 | 2007-10-10 | Merck & Co Inc | USE OF 2- (4-BENZYL) -1-PIPERIDINYL) METHYL | BENZIMIDAZOLE-5-OL DERIVATIVES AS ANTAGONISTS OF NR2B RECEPTORS |
WO2004110389A2 (en) * | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
US20040266808A1 (en) * | 2003-06-27 | 2004-12-30 | Kamen Barton A. | Treatment of antifolate neurotoxicity |
JP2007509150A (ja) * | 2003-10-21 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | 神経障害性疼痛の治療において有用なトリアゾロ−ピリダジン化合物および、この誘導体 |
US20060019968A1 (en) * | 2004-07-24 | 2006-01-26 | Laboratorios Dr. Esteve S.A. | Use of compounds active on the sigma receptor for the treatment of neuropathic pain |
MX2007000793A (es) * | 2004-07-24 | 2007-03-21 | Esteve Labor Dr | Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecanica. |
FR2873294B1 (fr) * | 2004-07-26 | 2008-05-09 | Greenpharma Sa Sa | Association de medicaments |
WO2006122035A2 (en) | 2005-05-06 | 2006-11-16 | University Of Maryland, Baltimore | Method for treating central pain syndrome or for inducing centrally generated pain in an animal model |
WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
WO2007070679A2 (en) * | 2005-12-14 | 2007-06-21 | Zars, Inc. | Compositions and methods for dermally treating pain |
KR100743255B1 (ko) * | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | T-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
US8586619B2 (en) * | 2007-03-12 | 2013-11-19 | Vm Therapeutics Llc | Agents of calcium ion channel modulators |
ES2842289T3 (es) | 2008-02-29 | 2021-07-13 | Vm Therapeutics Llc | Compuestos para tratar el síndrome del dolor y otros trastornos |
-
2009
- 2009-02-26 ES ES16170030T patent/ES2842289T3/es active Active
- 2009-02-26 EP EP09715280A patent/EP2252608A4/en not_active Withdrawn
- 2009-02-26 CN CN2009801070545A patent/CN101970427A/zh active Pending
- 2009-02-26 EP EP16170030.7A patent/EP3106166B1/en active Active
- 2009-02-26 WO PCT/US2009/035319 patent/WO2009108798A1/en active Application Filing
- 2009-02-26 DK DK16170030.7T patent/DK3106166T3/da active
- 2009-02-26 JP JP2010548872A patent/JP5723600B2/ja active Active
-
2010
- 2010-08-27 US US12/870,327 patent/US8865727B2/en active Active
-
2014
- 2014-09-09 US US14/481,398 patent/US8980900B2/en active Active
-
2015
- 2015-02-09 US US14/617,368 patent/US9402848B2/en active Active
- 2015-03-30 JP JP2015067995A patent/JP2015143255A/ja active Pending
-
2016
- 2016-07-14 US US15/210,102 patent/US9834555B2/en active Active
-
2017
- 2017-06-16 HK HK17106002.4A patent/HK1232162A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20110053960A1 (en) | 2011-03-03 |
EP2252608A4 (en) | 2012-10-03 |
WO2009108798A1 (en) | 2009-09-03 |
JP5723600B2 (ja) | 2015-05-27 |
JP2015143255A (ja) | 2015-08-06 |
EP3106166A1 (en) | 2016-12-21 |
JP2011513326A (ja) | 2011-04-28 |
US8865727B2 (en) | 2014-10-21 |
US8980900B2 (en) | 2015-03-17 |
CN101970427A (zh) | 2011-02-09 |
US20160318930A1 (en) | 2016-11-03 |
US20150150875A1 (en) | 2015-06-04 |
HK1232162A1 (zh) | 2018-01-05 |
ES2842289T3 (es) | 2021-07-13 |
US20140378476A1 (en) | 2014-12-25 |
US9402848B2 (en) | 2016-08-02 |
EP2252608A1 (en) | 2010-11-24 |
US9834555B2 (en) | 2017-12-05 |
EP3106166B1 (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2796469T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser | |
DK2170930T3 (da) | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme | |
DK2019683T4 (da) | Indgivelse af vækstfaktorer til behandling af CNS-lidelser | |
DK2240130T3 (da) | Indretning til behandling af fedme | |
DK2211846T3 (da) | Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser | |
DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
DK2445502T4 (da) | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser | |
DK2726511T3 (da) | Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser | |
DK2350416T4 (da) | Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude | |
DK3135672T3 (da) | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme | |
DK2073811T3 (da) | Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme | |
DK2084151T3 (da) | Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme | |
DK2894165T3 (da) | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser | |
DK2307042T3 (da) | Modulering af trpv: vps10p-domænereceptorsystem til behandlingen af smerte | |
DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
DK2240155T3 (da) | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler | |
DK2356093T3 (da) | Carbazolforbindelser og terapeutiske anvendelser af forbindelserne | |
DK2220116T3 (da) | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza | |
DK2114447T3 (da) | Forebyggelse og behandling af subkliniks pcvd | |
DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
DK2114419T3 (da) | Natriummetaarsenit til anvendelse i behandling af smerte og inflammation | |
DK2315532T3 (da) | Sammensætninger og fremgangsmåder til behandling af forstyrrelser, der er associeret med overvægtige dyr | |
DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser |